Posted by Michael Wonder on 11 May 2020
Health economic assessment of gene therapy Zynteglo in transfusion-dependent beta-thalassemia
11 May 2020 - TLV has developed a health-economic knowledge base for the Zynteglo gene therapy (autologous CD34-positive cells expressing the βA-T87Q globin gene).
The documentation is valid for the treatment of patients from 12 years of age and upwards with transfusion-dependent beta (β) -thalassaemia who do not have a β0 / β0 genotype for which allogeneic haematopoietic stem cell transplantation is suitable but lacking a donor.
